

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Suzhou Ribo Life Science Co., Ltd.

蘇州瑞博生物技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6938)

VOLUNTARY ANNOUNCEMENT

APPROVAL OF PHASE II CLINICAL TRIAL IN CHINA OF RBD5044

This announcement is made by Suzhou Ribo Life Science Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide shareholders of the Company (the “**Shareholders**”) and potential investors with an update on the Group’s research and development progress.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Group’s self-developed RBD5044 Injection was approved for Phase II clinical trial from the National Medical Products Administration in China.

RBD5044 is an APOC3-targeting siRNA. APOC3 is a protein synthesized almost exclusively in the liver that plays a critical role in lipid metabolism. RBD5044 addresses the complications associated with hypertriglyceridemia, making it a therapeutic option for managing lipid disorders.

RBD5044 Injection may not ultimately be successfully developed and commercialized. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Suzhou Ribo Life Science Co., Ltd.
LIANG Zicai
Chairman

Hong Kong, January 23, 2026

As of the date of this announcement, the executive Directors are Dr. LIANG Zicai, Dr. GAN Liming and Dr. ZHANG Hongyan, the non-executive Directors are Dr. QI Fei, Mr. LI Dongfang and Mr. LI Yuhui, and the independent non-executive Directors are Dr. YU Xuefeng, Mr. MA Chaochang and Mr. WANG Ruiping.